From Cancer Diagnosis to Prognosis Prediction... AI's Scope Expands

DeepBio Introduces 5 Deep Learning Cancer Diagnosis Studies at American Association for Cancer Research
Theragen Bio Completes Patent Acquisition for Patient Classification Device
Coreline Soft Launches Korea's First Automated Contouring Solution

[Asia Economy Reporter Lee Gwan-joo] The use of artificial intelligence (AI) in the pharmaceutical and bio industries, primarily applied in new drug development, is expanding across the entire digital healthcare industry. Recently, there has been a significant increase in the development and commercialization attempts of products that can assist in processes such as diagnosis, risk classification, and prognosis prediction of patients. The industry believes that the fields where AI can be applied are limitless and that domestic AI technology has sufficient competitiveness in the global market.

DeepBio’s Deep Learning Research on ‘Cancer Diagnosis and Prognosis Prediction’

According to the pharmaceutical and bio industry on the 15th, AI-based domestic digital healthcare companies are continuously entering the global market and filing patents. DeepBio, one of the leading domestic companies in AI-based cancer diagnosis, recently introduced five deep learning research studies related to cancer diagnosis and prognosis prediction at the American Association for Cancer Research (AACR) annual meeting held in New Orleans, USA. The abstracts adopted by DeepBio at this year’s AACR include ▲development of a common survival analysis model applicable to various cancer types ▲two studies related to survival analysis of breast cancer patients ▲diagnostic research on prostate cancer using frozen section specimens ▲and research on gene mutation association analysis of prostate cancer lesions.

DeepBio particularly introduced research results on a common survival analysis deep learning model applicable to various cancer types. In this study, a model trained with pancreatic cancer patient data accurately predicted the prognosis of rectal and breast cancer patients, confirming the existence of common histological features that can be used for prognosis prediction of various adenocarcinomas. Additionally, DeepBio recently obtained European medical device certification (CE-IVDD) for its AI-based prostate cancer diagnostic support software, ‘DeepDx Prostate.’ This software analyzes whole slide images of prostate biopsy tissues using AI to detect cancerous areas and classify severity. A DeepBio representative stated, "Cancer diagnosis and prognosis prediction are very important areas directly linked to patient treatment planning," adding, "Utilizing deep learning technology can help predict cancer prognosis more accurately and in various ways."

From Patient Classification to Treatment Planning

Theragen Bio completed patent acquisition earlier this month for ‘DeepOmics Marker™,’ an AI-based molecular subtype extraction device for patient classification. This program uses deep learning to effectively classify patients and derive key markers for each disease subtype, identifying personalized drugs or new drug development targets for each patient. Theragen Bio has established an AI-based patient-specific diagnostic prognosis analysis platform called ‘DeepOmics,’ which consists of four AI platforms across different fields, including the newly patented DeepOmics Marker, cancer vaccine research, patient drug response analysis, and therapeutic drug target selection.

Coreline Soft introduced ‘AVIEW ACS,’ Korea’s first AI-based fully automated contouring solution. Contouring is a preliminary step before establishing a cancer treatment plan, involving segmentation of organs in the treatment area captured by CT scans and ensuring appropriate radiation doses are delivered to cancerous regions. AVIEW ACS significantly reduces the time required for contouring tasks.

Currently, AI-based diagnostic and predictive programs are mainly developed for cancer patients. Due to the long-term treatment required and the considerable number of patients, demand remains steady, and these programs can benefit patients. The industry expects the scope of AI applications to be limitless in the future. Attempts to utilize AI are already ongoing in virtually all fields, including new drug development, radiology solutions, cancer treatment, and diagnosis. An industry official commented, "As AI technology continues to advance, the time required for commercialization is also significantly shortening," adding, "Domestic companies have sufficient competitiveness to succeed in the global market, so various AI-based initiatives are expected to continue."

This content was produced with the assistance of AI translation services.